EPHX2 and metabolic dysfunction-associated steatohepatitis: There is accumulating evidence that sEH expression is induced in many liver pathologies, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, and portal hypertension (PTH) [40,41,42,43,44,45].